---
title: Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A
date: '2024-12-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39655790/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241211171327&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Gene therapy for hemophilia A with the use of lentiviral
  vector-transduced autologous HSCs resulted in stable factor VIII expression, with
  factor VIII activity correlating to vector copy number in the peripheral blood.
  (Funded by the Ministry of Science and Technology, Government of India, and others;
  ClinicalTrials.gov number, NCT05265767; Clinical Trials Registry-India number, CTRI/2022/03/041304.).
  ...'
disable_comments: true
---
CONCLUSIONS: Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII expression, with factor VIII activity correlating to vector copy number in the peripheral blood. (Funded by the Ministry of Science and Technology, Government of India, and others; ClinicalTrials.gov number, NCT05265767; Clinical Trials Registry-India number, CTRI/2022/03/041304.). ...